Zelira Therapeutics Ltd
ASX:ZLD
Zelira Therapeutics Ltd
ASX:ZLD
Price:
0.5
AUD
Market Closed
Market Cap:
AU$6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Zelira Therapeutics Ltd
ASX:ZLD
|
AU |
|
A
|
Alok Industries Ltd
NSE:ALOKINDS
|
IN |
|
Global Energy Ventures Ltd
ASX:GEV
|
AU |
|
P
|
Paysauce Ltd
NZX:PYS
|
NZ |
|
D
|
Discovery Ltd
JSE:DSY
|
ZA |
|
BlackRock TCP Capital Corp
NASDAQ:TCPC
|
US |
|
Chahua Modern Housewares Co Ltd
SSE:603615
|
CN |
|
Emerge Gaming Ltd
ASX:EM1
|
AU |
|
Qnb Finansal Kiralama AS
IST:QNBFK.E
|
TR |
|
Q
|
Q & M Dental Group (Singapore) Ltd
XBER:QMBN
|
SG |
|
J
|
Jiangsu Zenergy Battery Technologies Group Co Ltd
HKEX:3677
|
CN |
|
SICO Saudi REIT Fund
SAU:4337
|
SA |
|
P
|
Procook Group PLC
LSE:PROC
|
UK |
|
S
|
SIK Cheong Bhd
KLSE:SCB
|
MY |
|
GE Vernova Inc
MIL:1GEV
|
US |
|
CGI Inc
NYSE:GIB
|
CA |
Multiples-Based Value
The Multiples-Based Value of one
ZLD
stock under the Base Case scenario is
hidden
AUD.
Compared to the current market price of 0.5 AUD,
Zelira Therapeutics Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ZLD Multiples-Based Value
LOCKED
Multiples Across Competitors
ZLD Competitors Multiples
Zelira Therapeutics Ltd Competitors
Zelira Therapeutics Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Zelira Therapeutics Ltd
ASX:ZLD
|
5.9m AUD | 8 498 | -1.6 | -3 | -3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
